oin Dr. Benjamin Alouf, board certified Pediatrician and Chief Medical Officer at Limbix, on a Flip Side conversation about the role these factors and more play in a young person’s mental health journey. Dr. Alouf and the diverse team of clinicians, product designers, researchers, and engineers at Limbix are on a mission to make mental health treatment accessible to young people who need it the most, when and where they need it the most.
Investors are pumping money into startups that offer pediatric mental-health services.
The expansion of virtual platforms for mental and behavioral health care is welcome, but with such rapid growth comes the challenge of determining which platforms or programs are evidence-based. Hospital and health system leaders must determine which ones are clinically appropriate for specific populations and patients. Here are ways provider organizations can help shape the development and use of mental health apps and platforms.
Limbix is excited to announce a partnership with Children's Hospital Los Angeles (CHLA) for a research study to evaluate SparkRx, an adjunct treatment for adolescents with symptoms of depression, in specialty medical care settings.
Digital mental health interventions, or digital therapeutics, have the potential to transform the field of mental health. They provide the opportunity for increased accessibility, reduced stigma, and daily integration with patient's lives.
On the latest instalment of the pharmaphorum podcast, editor in chief Jonah Comstock hosts Dr Benny Alouf, chief medical officer at Limbix to discuss his company’s digital therapeutic for teen depression.
Developers of digital therapeutics (DTx) need to embrace regulation as a “necessary evil” and work with clinicians from the beginning of development to pass the regulatory procedure, said an expert who developed FDA-authorized DTx.
Bixink developed and sold the domestic exclusive development and commercialization of 'SparkRx', a digital treatment for adolescent depression developed by Limbix Health of the United States, which owns the 'Limbix Synapse Platform', a digital treatment for adolescent mental illness. announced that a commercialization agreement had been signed.
Mental health issues among teens and young adults have risen dramatically over the past decade. Jessica Lake, chief science officer at Limbix, tells us about SparkRx, a digital therapeutics app aimed to help treat adolescent depression.
Mental health care is at a breaking point in Ohio, with patients and providers in a desperate situation.Adding to the need of those with pre-existing conditions, there are now additional people with pandemic-triggered mental health issues, and a whole new wave of people finally seeking out mental health care now that stigmas are disappearing.
Interview of Jon Sockell, Limbix COO: What are prescription digital therapeutics and how could/can they support the mental health of young people?
Ben Lewis, CEO of digital therapeutics platform Limbix, joins Cheddar News to discuss the app helping teens in early stages of depression.
The COVID-19 pandemic has reshaped many aspects of our lives. One particular field that has flourished on a larger scale is that of digital therapeutics (DTx) and digital health in general.
The area of digital therapeutics is growing rapidly, and in this piece Ben Hargreaves examines why this is the case, how broadly these therapies can be applied and why investment in the area is mounting.
Many Americans have been battling mental health throughout the Covid-19 pandemic, but doctors are hoping a new tool can help struggling teens through their smartphones. Chief Science Officer at Limbix, Dr. Jessica Lake, joins News NOW to explain how her company’s digital therapy aims to help teens that are fighting depression.
To better meet the needs of patients, providers can improve access to treatment and offer more immediate solutions through the use of prescription digital therapeutics (PDTs).
Limbix, a prescription digital therapeutic company developing mental health treatments for adolescents, was named to CB Insights Digital Health 150 List, which recognizes the most promising private digital health companies in the world.
Limbix, maker of a prescription digital therapeutic aimed at treating depression in teens, scooped up $15 million in Series A2 funding.
Limbix was founded in 2016, and has about 30 employees, with plans to add 30 more by the second quarter of 2022. So far the company has raised $9 million in Series A funding, which closed in May 2020. That round was led by by GSR Ventures, with participation from existing investors Sequoia Capital, Storm Ventures, NextGen Venture Partners, and BIXINK Therapeutics.
Limbix is moving ahead with plans to file for FDA approval of its SparkRx digital therapeutic (DTx) for adolescents with symptoms of depression after reporting positive results in a clinical trial.
Limbix Health Inc. released data demonstrating a 21% remission rate and 29% response rate for Sparkrx, its prescription digital therapeutic, in adolescents who completed the program as recommended.
Program delivered on smartphone is based on core principles of cognitive behavioral therapy, with focus on behavioral activation.Trial results demonstrate clinically meaningful reduction in depression symptoms.Completing SparkRx as recommended results in statistically significant reduction in symptoms compared to control
Limbix announced on Friday the launch of SparkRx, which it says is the first evidence-based digital therapeutic (DTx) for adolescents and young adults aged 13 to 22 with symptoms of depression. The programme, which is delivered on a smartphone, is based on the core principles of cognitive behavioural therapy, with a focus on behavioural activation.
Benjamin Alouf, M.D., chief medical officer of Limbix, will present clinical data demonstrating the efficacy of SparkRx in adolescents with moderate to severe depressive symptoms at the upcoming American Academy of Pediatrics (AAP) National Conference. The virtual conference begins Oct. 8.
Today, Limbix, a prescription digital therapeutic company developing mental health treatments for adolescents, announced the appointment of Jessica Lake, Ph.D., as chief science officer and Aarthi Padmanabhan, Ph.D., as chief research officer.
US-based startup Limbix develops prescription digital therapeutic solutions for young adults. The platform is designed to offer cognitive behavioral therapy-based programs.
Today, Limbix, a prescription digital therapeutic company developing mental health treatments for adolescents, announced that Benjamin Alouf, M.D., has been named chief medical officer. Dr. Alouf is a board-certified pediatrician with more than two decades of experience overseeing and executing clinical programs and policies.
When the pandemic began more than a year ago, the country changed overnight. For teens everywhere, there were a lot of unexpected adjustments -- schools closed, extracurricular activities were non-existent and friendships were reduced to Zoom hangouts and virtual TikTok challenges.
Health care has become increasingly digitized ever since the beginning of the pandemic. Growing in popularity, telehealth services also have the capacity to alleviate staffing needs.
Dr. Gold is a pediatric psychologist and full professor at USC Keck School of Medicine and has been working with teens and children for over 30 years.
The $3.6M NIMH Fast-Track SBIR grant will support a large-scale pivotal clinical trial conducted in partnership with the Duke Clinical Research Institute.
KidsX brings together top children’s hospitals and health startups to create digital solutions that will transform pediatric care for children and their families
The Silicon Valley startup plans to start its registration-directed study of Limbix Spark in the earlier part of next year and - if successful - would anticipate FDA clearance in early 2022.
The INVEST Digital Health Virtual conference Pitch Perfect competition, from September 21-25, had some intense competition between the healthcare startup participants. Thanks to all the entrepreneurs, judges and sponsors who took part.
Limbix CMO Dr. Cruz discusses the difference between 510(k) clearances and enforcement discretions, and why research should go beyond the FDA threshold.
The West Coast Consortium for Technology & Innovation in Pediatrics (CTIP) announced in April the launch of its COVID-19 FlexGrants
GSR Ventures led the round with participation from Sequoia Capital, Storm Ventures, NextGen Venture Partners and BIXINK Therapeutics.
The new funding enables further research and development of the company’s flagship product, Limbix Spark, the first prescription digital therapeutic designed to treat adolescents with depression.May 6, 2020
Welcome to #TheNextWave, a conversation series with the Headstream Accelerator Finalists who want to use social tech for the good of humanity.
This year's cohort includes 27 companies that are working on everything from digital therapeutics to care coordination tools, to clinician workflow platforms, to opioid alternatives.
For media inquiries and our press kit, please contact press@limbix.com
